AI Drug Discovery Company Elix Commences Joint Research With Proprietary Screening Technology Holder SEEDSUPPLY

TOKYO–(BUSINESS WIRE)–Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”) and SEEDSUPPLY Inc. (CEO: Naoki Tarui / HQ: Kanagawa, hereinafter “SEEDSUPPLY”) hereby announces the start of joint research.

SEEDSUPPLY ( offers an agile drug discovery process for small molecules that uses linkage selection technology as a proprietary compound screening method. This technology can perform compound screening of any protein or RNA, thus providing drug discovery seeds for a variety of drug discovery targets, including those for which biochemical activity measurement is difficult. In addition, a binding compound database built for specific drug discovery target classes will be used for target selection, improving the efficiency and success rate of drug discovery processes. In addition, the database presents the potential for wider application.

Also Read :  China tops U.S. for first time in this ranking of world's 'best' universities

Elix ( is an AI drug discovery company with the mission to “Rethink Drug Discovery”. To reduce the cost and time while increasing the success rate of the drug discovery pipeline, Elix focuses on the use of machine learning in projects aimed at pharmaceutical companies, universities and research institutes. Elix developed and released “Elix Discovery™”, the all-in-one platform for AI drug discovery, providing everything from models for property prediction and molecular design, to consulting and implementation support in one package (https://www.elix) . In addition to currently providing drug discovery support, Elix is ​​also considering future in-house drug discovery.

Also Read :  A former NBA champion is changing 'how the world builds' to fight the climate crisis

In this joint research project, SEEDSUPPLY will use Elix’s proprietary AI technology with the aim of dramatically increasing the efficiency of screening processes. Elix will incorporate SEEDSUPPLY’s wealth of data, particularly its data on key drug discovery targets such as membrane proteins, into the AI ​​training pipeline, thereby advancing technology for in silica techniques to screen compounds with superior properties.

Elix and SEEDSUPPLY aim to leverage their respective strengths to lower the cost and time of small molecule drug discovery and address targets that have proven difficult for conventional drug discovery approaches.

Also Read :  Level Infinite teases PUBG Mobile Martial Arts Showdown mode

  • Comments from Elix CEO Shinya Yuki

    By combining the data obtained through SEEDSUPPLY’s proprietary technology and our proprietary AI models, we hope to find even more unique technological developments. We believe that this technology will enable great possibilities in screening for very difficult targets at low cost in short times, and in efficiently searching vast chemical spaces.

  • Comments from SEEDSUPPLY CEO Naoki Tarui

    Our company’s mandatory composite database is of the highest quality, as all its content has been measured using the same method. By combining it with Elix’s superior AI technology, we hope to create new developments in AI drug discovery technology.


Leave a Reply

Your email address will not be published.

Related Articles

Back to top button